Understanding the immunology of the Zostavax shingles vaccine.

Understanding the immunology of the Zostavax shingles vaccine.
Curr Opin Immunol. 2019 Apr 07;59:25-30
Authors: Sullivan NL, Eberhardt CS, Wieland A, Vora KA, Pulendran B, Ahmed R
Abstract
Zostavax is a live-attenuated varicella zoster virus (VZV) vaccine recommended for use in adults >50 years of age to prevent shingles. The main risk factor for the development of shingles is age, which correlates with decreasing cell-mediated immunity. These data suggest a predominant role of T cell immunity in controlling VZV latency. However, other components of the immune system may also contribute. In this review, we will discuss how the immune system responds to Zostavax, focusing on recent studies examining innate immunity, transcriptomics, metabolomics, cellular, and humoral immunity.
PMID: 30970291 [PubMed - as supplied by publisher]

Source: Current Opinion in Immunology - April 6, 2019 Category: Allergy & Immunology Authors: Sullivan NL, Eberhardt CS, Wieland A, Vora KA, Pulendran B, Ahmed R Tags: Curr Opin Immunol Source Type: research